SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

Key Points

• SEMA3B shows an association with disease activity and infliximab response in patients.
• Participants with higher SEMA3B levels often demonstrate varied responses to infliximab treatment.
• Assessment involved examining SEMA3B levels in patients with inflammatory bowel disease (IBD).
• These findings indicate that SEMA3B may have implications in treatment response but not in colitis development.

Abstract